Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Open Access
- 1 October 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 30 (4) , 1054-1058
- https://doi.org/10.1002/hep.510300409
Abstract
The natural history of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients has never been studied according to the concept of liver fibrosis progression. The aim of this work was to assess the fibrosis progression rate in HIV-HCV coinfected patients and in patients infected by HCV only. A cohort of 122 HIV-HCV coinfected patients was compared with a control group of 122 HIV-negative HCV-infected patients. Groups were matched according to age, sex, daily alcohol consumption, age at HCV infection, and duration and route of HCV infection. The fibrosis progression rate was defined as the ratio between fibrosis stage (METAVIR scoring system) and the HCV duration. The prevalence of extensive liver fibrosis (METAVIR fibrosis scores 2, 3, and 4) and moderate or severe activity were higher in HIV-infected patients (60% and 54%, respectively) than in control patients (47% and 30%, respectively; P < .05 and P < .001, respectively). The median fibrosis progression rate in coinfected patients and in control patients was 0.153 (95% confidence interval [CI], 0.117-0.181) and 0.106 (95% CI, 0.084-0.125) fibrosis units per year, respectively (P < .0001). HIV seropositivity (P < .0001), alcohol consumption (>50 g/d, P = .0002), age at HCV infection (P< .0001), and severe immunosuppression (CD4 count ≤200 cells/μL,P< .0001) were associated with an increase in the fibrosis progression rate. In coinfected patients, alcohol consumption (>50 g/d), CD4 count (≤200 cells/μL), and age at HCV infection (P< .0001, respectively) were associated with a higher fibrosis progression rate. HIV seropositivity accelerates HCV-related liver fibrosis progression. In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate.Keywords
This publication has 27 references indexed in Scilit:
- Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug usersJournal of Hepatology, 1998
- Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis CThe Lancet, 1997
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Natural history of liver fibrosis progression in patients with chronic hepatitis CThe Lancet, 1997
- Human immunodeficiency virus infection modified the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosisJournal of Hepatology, 1997
- Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired Hepatitis CEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virusJournal of Medical Virology, 1991
- Prevalence of Antibody to Hepatitis C Virus in Patients Infected with the Human Immunodeficiency VirusThe Journal of Infectious Diseases, 1991
- High Prevalence of Antibody to Hepatitis C Virus in Multitransfused Hemophiliacs with Normal Transaminase LevelsAnnals of Internal Medicine, 1990